Cobas 602

The sex, age, BMI, adverse reactions and other clinical characteristics of each vaccination recipient were collected. Our study detected SARS-CoV-2 spike-specific IgG and IgM (S-IgG and S-IgM), routine hematologic parameters at each timepoint and measured biochemical markers of the enrolled participants prevaccination. Levels of S-IgG and S-IgM were assessed using a chemiluminescent assay kit according to the manufacturer’s instructions (Autobio Diagnostics, Zhengzhou, China). S/CO values were obtained, and a value ≥ 1.0 was qualitatively defined as positive. Hematologic markers were detected using a Sysmex XN2000 analyzer (Sysmex, Japan). Levels of liver function markers were tested using Roche kits on a Roche Cobas 702 biochemical analyzer (Germany). Serum levels of inflammatory markers, serum amyloid A (SAA) and C-reactive protein (CRP) were measured using latex enhanced immune turbidimetry kits (SAA, Weimi Bio-Tech, China; CRP, SEKISUI, Japan) on an automatic biochemical analyzer (Roche Cobas 702, Germany), while estradiol (E2) and thyroid-related hormones were assessed using Roche kits (Germany) by an electrochemiluminescence analyzer (Roche Cobas 602, Germany). All tests were performed according to the manufacturer’s protocols.

The blood samples were collected from the inferior vena cava. The activity of lactate dehydrogenase (LDH) and creatine kinase MB isoenzyme (CK-MB) in the mouse serum were measured by an automatic biochemical analyzer (Roche Cobas C702, Roche, Switzerland). The content of cardiac troponin T (cTnT) in the mouse serum was measured by an electroluminescent detection system (Roche Cobas 602, Roche, Switzerland).

After fasting for 10 hours overnight, the venous blood was drawn by a nurse in the morning. Roche cobas 8000 (Roche Diagnostics Ltd, Shanghai, China) was used to measure the levels of fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), calcium (Ca), phosphorus (P), albumin (ALB), ALT, AST, ALP, γ-GT, Cr, and UA. The level of hemoglobin Alc (HbAlc) was measured with the high pressure liquid chromatography method. Roche cobas 602 (Roche Diagnostics Ltd, Shanghai, China) was used to analyze the levels of fasting insulin (FINS). Insulin resistance (IR) and β-cell function were indirectly ascertained by the Homeostasis Model Assessment (HOMA) as follows: HOMA-IR=FBG (mmol/L)×FINS (mIU/L) /22.5; HOMA-β=20×FBG (mmol/L) / (FINS [mIU/L] -3.5) (%).

Plasma glucose was analyzed following centrifugation by hospital laboratory staff at the shortest possible interval following sample collection using the AU680 Chemistry analyser (Beckman Coulter Inc., High Wycomb, UK) and the hexokinase method. Bloods collected for serum analysis of insulin, lipid and inflammatory markers were centrifuged at 4 °C within an hour of sample collection for 5 min. The separated serum was immediately frozen at −20 °C, with subsequent transfer to a −80 °C freezer. Insulin and c-peptide were quantified by automated immune-assay (Roche Cobas 602; Roche Diagnostics, Basel, Switzerland) with typical CVs < 5%. Total cholesterol, high density lipoprotein cholesterol (HDL-C) and triglycerides were analyzed on a Roche Cobas 702 analyser (Roche Diagnostics). Low density lipoprotein cholesterol (LDL-C) was estimated using the equation of Friedewald et al. [26 (link)]. Maternal C3 was analyzed according to the immunoturbidimetric assay for serum complement C3 (Rx Daytona; Randox Laboratories, Antrim, UK). CRP was analyzed using a biochip array (Evidence Investigator™ Metabolic Syndrome Array II Randox Laboratories, Antrim, UK).

First, we collected 3 mL of venous fasting blood from all participants in serum separation tubes and centrifuged it immediately at 3000 rpm for 5 min. The supernatant was collected to measure serum tumor markers. Serum alpha-fetoprotein (AFP), CA125, CA153, CA199, and carcinoembryonic antigen (CEA) levels and exosomal AFP, CA125, CA153, CA199, and CEA levels of the non-OC group were detected using the Beckman DXl800 chemiluminescence immunoassay device (Beckman Coulter Inc., Brea, CA, USA). Serum HE4 levels of the non-OC group were detected using the Roche Cobas 602 analyzer (Roche Diagnostics, Basel, Switzerland). Serum CA125 and HE4 and exosomal CA125 and HE4 levels of the OC and NC groups were also detected using these methods. Fig. 1B shows the specific process of chemiluminescence detection of CA125.

Total testosterone levels (normal range 250–1100 ng/mL) were measured by electro-chemiluminescence immunoassay (Cobas 602, Roche Diagnostics International Ltd, Switzerland) and free testosterone (normal range 35–155 pg/mL) by liquid chromatography tandem mass spectroscopy (Quest Diagnostics Nichols Institute, Valencia, CA). Hypogonadism was defined as total testosterone less than 250 ng/mL.